Viewing nowADMed Tablets 10 mg (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Korea Pharmaceutical Co., Ltd.

MFDS item code 200501885 · Notified 2005.01.28 · Insurance code 642801020
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer’s disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only when a caregiver is able to check the patient's medication use regularly. The diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed regularly. This medicine is administered orally once daily and should be taken at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg daily for 7 days. Week 2 (Days 8–14): Administer 10mg daily for 7 days. Week 3 (Days 15–21): Administer 15mg daily for 7 days. From Week 4 onward: Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.
This medication should not be used in patients with hypersensitivity to the ingredients, severe hepatic impairment, or severe renal impairment. Additionally, it contains lactose, so individuals with genetic issues such as galactose intolerance, Lapp lactase deficiency, and glucose-galactose malabsorption should not take this medication. Patients with epilepsy or a history of seizures, or individuals prone to seizures, should use this medication with caution. Taking NMDA antagonists such as amantadine, ketamine, or dextromethorphan together may increase or prolong central nervous system side effects; therefore, co-administration should be avoided. Patients with risk factors that can increase urinary pH, such as dietary changes or specific urinary tract infections, should be carefully monitored. Patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension should use this medication cautiously due to a lack of clinical trial data. While taking this medication, side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur; if symptoms are severe, consult healthcare professionals. Furthermore, this medication may interact with various other medications, so it is essential to inform any healthcare providers about other medications being taken. Pregnant women should only take this medication when absolutely necessary, as it may pose risks to the fetus, and nursing mothers are advised to discontinue breastfeeding. The safety and efficacy of this medication in children and adolescents under 18 years of age have not been established, so it is best avoided. Overdosage may cause symptoms such as confusion, drowsiness, hallucinations, and seizures, and immediate medical care should be sought. This medication may affect the patient's reaction time, so caution is advised when driving or operating machinery. Finally, it is essential to keep this medication out of the reach of children and not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is best kept at temperatures between 1 degree and 30 degrees Celsius. Proper storage will ensure the medication's effectiveness.
White elongated film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Korea Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.